Large food and alcohol companies are undermining public health

Prof Rob Moodie, Melbourne School of Population and Global Health, Malawi College of Medicine
Large food and alcohol companies are undermining public health ( Prof Rob Moodie, Melbourne School of Population and Global Health, Malawi College of Medicine )
6 Nov 2018

Using genetics to close the knowledge gap on cancer causation

Dr Paul Brennan, International Agency for Research On Cancer (IARC) (France
Using genetics to close the knowledge gap on cancer causation ( Dr Paul Brennan, International Agency for Research On Cancer (IARC) (France )
6 Nov 2018

The IMpower-132 trial for non small cell lung cancer

Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US
The IMpower-132 trial for non small cell lung cancer ( Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US )
29 Oct 2018

Current clinical landscape for ALK non-small cell lung cancer patients

Dr Riyaz Shah and Dr Maurice Perol
Current clinical landscape for ALK  non-small cell lung cancer patients ( Dr Riyaz Shah and Dr Maurice Perol )
26 Oct 2018

Latest advances in treatment for ALK positive NSCLC

Prof Gordon McVie, Dr Lázaro Quintela
Latest advances in treatment for ALK positive NSCLC ( Prof Gordon McVie,  Dr Lázaro Quintela )
26 Oct 2018

Highlights in early non-metastatic NSCLC and thoracic tumours

Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain
Highlights in early non-metastatic NSCLC and thoracic tumours ( Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain )
26 Oct 2018

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )
26 Oct 2018

Highlights in SCLC from ESMO 2018

Dr Noemi Reguart - University of Barcelona, Barcelona, Spain
Highlights in SCLC from ESMO 2018 ( Dr Noemi Reguart - University of Barcelona, Barcelona, Spain )
26 Oct 2018

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC

Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018

ASCEND-8: safety data of ceritinib with or without food in NSCLC

Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea
ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )
26 Oct 2018

Lung highlights from ESMO 2018

Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy
Lung highlights from ESMO 2018 ( Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy )
26 Oct 2018

Erlotinib for neoadjuvant treatment of EGFR NSCLC

Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
Erlotinib for neoadjuvant treatment of EGFR NSCLC ( Dr Wen-Zhao Zhong - Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China )
26 Oct 2018